Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

59.27 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
66 67 Next >
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
From Karuna Therapeutics, Inc.
Via Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
From Bristol Myers Squibb
Via Business Wire
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
Is Bristol Myers Squibb Stock a Buy Now?
The answer might depend on the kind of investor you are. 
Via The Motley Fool
Is NYSE:BMY a Good Fit for Dividend Investing?
Balancing Dividends and Fundamentals: The Case of BRISTOL-MYERS SQUIBB CO (NYSE:BMY). 
Via Chartmill
3 Potential Turnaround Stocks to Buy for Big Rewards in 2024
There was plenty to get excited about in 2023 and even more to get excited about with turnaround stocks in the new year. 
Via InvestorPlace
Better Dividend Stock: Bristol Myers Squibb or Merck?
These two pharma stocks have sizable dividend yields. Which is the better buy right now? 
Via The Motley Fool
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
He posits that such actions have negatively impacted stock valuations. 
Via Benzinga
7 Stocks with Strong Insider Buying: December 2023
Here are just a few of the top stocks with strong insider buying that all investors may want to watch heading into 2024. 
Via InvestorPlace
Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal
SystImmune, the Seattle arm of Chengdu’s Biokin Pharma, out-licensed global rights (ex-China) for a bispecific ADC to Bristol Myers Squibb in a $8.4 billion agreement. 
Via Talk Markets
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)  
Via Benzinga
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
From Bristol Myers Squibb
Via Business Wire
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
From Bristol Myers Squibb
Via Business Wire
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
From Bristol Myers Squibb
Via Business Wire
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
From Bristol Myers Squibb
Via Business Wire
3 Dividend Stocks Trading at 52-Week Lows
All three of these companies have seen brighter days. 
Via The Motley Fool
Insiders Buying Bristol-Myers Squibb And 3 Other Stocks
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Why Bristol Myers Squibb's Shares Are Gaining Today?
Bristol Myers Squibb & Co (NYSE: BMY) released topline data from Phase 3 CheckMate -8HW trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to the investigator’s choice of chemotherapy as a... 
Via Benzinga
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers
The White House is endorsing a contentious power that permits the government to reclaim patents for specific  
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
Investors hunt for new opportunities in stocks that have been discounted & now present promising options for recovery. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Dirt-Cheap Stocks That Could Skyrocket
Low valuations don't always guarantee gains are in the offing. You need a company firing on all cylinders, too. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.